Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000700642 | SCV000829405 | uncertain significance | Hereditary spastic paraplegia 11 | 2022-04-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 1601 of the SPG11 protein (p.Gln1601Glu). This variant is present in population databases (rs764442362, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with SPG11-related conditions. ClinVar contains an entry for this variant (Variation ID: 577803). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002334347 | SCV002636415 | uncertain significance | Inborn genetic diseases | 2022-01-07 | criteria provided, single submitter | clinical testing | The p.Q1601E variant (also known as c.4801C>G), located in coding exon 28 of the SPG11 gene, results from a C to G substitution at nucleotide position 4801. The glutamine at codon 1601 is replaced by glutamic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |